Huaxia Ophthalmology: The company will fully consider the macro environment, overseas market demand, and actual business operations, and will explore the overseas market at the appropriate time.

Securities Star News, Huaxiayanke (301267) responded to investor questions on the investor relations platform on March 9.

Investor: During the Fourth Session of the 14th National People’s Congress, the economic-themed press conference for this year first proposed the goal of financial coordination to reduce the financing costs for private enterprises and vigorously develop medical outbound services and trade. Your company has clearly begun overseas expansion focusing on Eurasia and is considering acquiring upstream ophthalmic equipment and consumables manufacturers. How does your company plan to turn its leading domestic technologies and services in ICL, refractive surgery, and cataracts into a competitive advantage abroad to compete with international ophthalmology giants? Additionally, what are the specific pathways and timelines for the company to achieve industry chain integration and cost reduction through acquisitions of upstream ophthalmic equipment and consumables manufacturers?

Huaxiayanke Secretary: Dear investor, thank you for your interest in Huaxiayanke. Overseas markets are an important part of our strategic layout. Over the years, the company has maintained good relationships with ophthalmology peers worldwide through academic exchanges, educational activities, and public welfare projects like “Bright Journey,” establishing a solid foundation for overseas cooperation and development. After years of development, we have built a standardized diagnosis and treatment service system and a mature management model, and have established a reputable “Huaxiayanke” brand. We will fully consider macroeconomic conditions, overseas market demand, and our operational realities to explore international markets at the appropriate time. Meanwhile, we remain attentive to and actively seek opportunities along the industry chain, upstream and downstream. Any relevant progress will be disclosed in strict accordance with legal and regulatory requirements. Thank you again for your support of Huaxiayanke!

The above content is compiled from publicly available information by Securities Star, generated by AI algorithms (Network Information Calculation Backup No. 310104345710301240019), and does not constitute investment advice.